| GOSSAMER BIO INC. |
| USA |
| Gesundheit |
| US38341P1021 / A2PCBS |
| 4GB (Frankfurt) / GOSS (NASDAQ) |
| FRA:4GB, ETR:4GB, 4GB:GR, NASDAQ:GOSS |
| - |
| https://www.gossamerbio.c.. |
|
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious cardiopulmonary and immune-mediated diseases. Its lead program is seralutinib, an investigational inhaled therapy being studied for pulmonar..
>Volltext.. |
| 73.8 Mio. EUR |
| 58.94 Mio. EUR |
| 45.89 Mio. EUR |
| -135.79 Mio. EUR |
| -107.84 Mio. EUR |
| -0.49 EUR |
| 34.5 Mio. EUR |
| 35.43 Mio. EUR |
| -141.74 Mio. EUR |
| 0.41 |
| 36.6% |
| 6.91% |
| - |
| - |
| - |
| - |
| GOSSAMER BIO |
| 10.09.26 |
|